Evaluation of Levofloxacin Release Characteristics from a Human Foldable Capsular Vitreous Body In Vitro
Authors:
Open Access
- 26 October 2011
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 28 (1) , 33-40
Abstract
Purpose: We have manufactured a novel human foldable capsular vitreous body (FCVB). In this article, we determine whether the human FCVB releases levofloxacin in vitro and evaluate the release characteristics. Methods: Levofloxacin at dosages of 100, 250, and 500 μg/mL in 4.0 mL H 2 O was injected into the novel human FCVB; then, the capsules were immersed in cups of modified Franz diffusion cells. Two hundred microliters of liquid was aspirated at intervals of 10, 20, 40, 60, 120, 180, 240, 300, and 360 min. The levofloxacin concentrations in the cups were detected using the liquid chromatographic-tandem mass spectrometry (HPLC-MS/MS) method. Five hundred μg/mL levofloxacin liquor at volumes of 4.0, 5.0, and 6.0 mL was injected into the novel human FCVB, and the release characteristics were detected for each. The capsules of the FCVB were observed under scanning electron microscopy before and after the release study. Results: The novel human FCVB released levofloxacin in a time-dependent manner under 100, 250, and 500 μg/mL dosages from 10 to 360 min. Particularly in the 250 μg/mL levofloxacin group, the concentration ( Q ) had a good linear relationship with time ( t 1/2 ), Q =1.3381 t 1/2 +10.2818 (r=0.9954, Higuchi equation). The human FCVB released levofloxacin in a dose-dependent manner under 100, 250, and 500 μg/mL dosages from 10 to 360 min in the total tendency, but the 500 μg/mL group released less levofloxacin than the 250 group at 300 and 360 min. The human FCVB did not release levofloxacin in a volume-dependent manner with 4.0, 5.0, and 6.0 mL volume. The 4.0-mL volume group released more levofloxacin than the other 2 volume groups. Numerous 300-nm-mili apertures were observed in the capsule of the FCVB at the beginning and end of this observation. Conclusions: A human FCVB can sustainably, in vitro , mechanically release levofloxacin in both a time-dependent and dose-dependent manner, but not in a volume-dependent manner. This study sets forth a novel combined research and therapeutic strategy as a vitreous substitute and intravitreal drug delivery system for the treatment of bacterial endophthalmitis.Keywords
This publication has 25 references indexed in Scilit:
- Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitisBritish Journal of Ophthalmology, 2008
- Bacterial endophthalmitis: Therapeutic challenges and host–pathogen interactionsProgress in Retinal and Eye Research, 2007
- Endogenous bacterial endophthalmitis: A 17-year prospective series and review of 267 reported casesSurvey of Ophthalmology, 2003
- A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitisOphthalmology, 2003
- Bacterial Endophthalmitis: Epidemiology, Therapeutics, and Bacterium-Host InteractionsClinical Microbiology Reviews, 2002
- Vancomycin and ceftazidime incompatibility upon intravitreal injectionBritish Journal of Ophthalmology, 2000
- Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?American Journal of Health-System Pharmacy, 1997
- Spectrum and Susceptibilities of Microbiologic Isolates in the Endophthalmitis Vitrectomy StudyAmerican Journal of Ophthalmology, 1996
- Results of the Endophthalmitis Vitrectomy StudyArchives of Ophthalmology (1950), 1995
- Physical Incompatibility of Vancomycin and Ceftazidime for Intravitreal InjectionArchives of Ophthalmology (1950), 1993